PRTC Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	1 464.00
Średni wolumen	2 806.00
Kapitalizacja rynkowa	740.66M
EPS	$0 ( 2023-07-28 )
Następna data zysków	( $0 ) 2024-06-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.41
ATR14	$0 (0.00%)

PureTech Health plc Korelacja

10 Najbardziej pozytywne korelacje
NESR	0.886
SPLK	0.881
SFBC	0.866
MRM	0.86
ARNA	0.856
FSTR	0.85
RCII	0.848
HBANO	0.847
EGLE	0.847
TIG	0.846

10 Najbardziej negatywne korelacje
LMDX	-0.874
AEHR	-0.868
MHUA	-0.86
AVXL	-0.859
OFLX	-0.856
ETSY	-0.855
OSMT	-0.853
VMAR	-0.853
ZSAN	-0.848
ZKIN	-0.841

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

PureTech Health plc Finanse

Annual	2023
Przychody:	$3.33M
Zysk brutto:	$-1.60M (-48.14 %)
EPS:	$-2.38

FY	2023
Przychody:	$3.33M
Zysk brutto:	$-1.60M (-48.14 %)
EPS:	$-2.38

FY	2022
Przychody:	$2.09M
Zysk brutto:	$2.09M (100.00 %)
EPS:	$-1.300

FY	2021
Przychody:	$9.98M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.12

Financial Reports:

No articles found.

PureTech Health plc

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.